Business Context and Reporting Period
The filing is Pono Capital Two, Inc.’s Form 10-K for the fiscal year ended December 31, 2023, filed March 18, 2024. The supplied metadata identifies SBC Medical Group Holdings Inc., but the filing registrant is Pono Capital Two, Inc., a Delaware special purpose acquisition company with no operating business or revenue as of year-end.
Pono was formed to complete a business combination, with a stated focus on disruptive technology companies in Asia, particularly Japan. It entered into a merger agreement with SBC Medical Group Holdings Incorporated in January 2023. The proposed transaction would combine Pono with SBC and make SBC Medical Group Co., Ltd. and certain related service entities subsidiaries of the combined company.
Financial Results and Liquidity
| Metric | Year ended December 31, 2023 | Prior comparable period* |
|---|---|---|
| Operating revenue | $0 | $0 |
| Interest and dividend income | $2.641 million | $1.345 million |
| Operating and formation costs | $1.635 million | $0.382 million |
| Loss from operations | $(1.773) million | $(0.544) million |
| Net income | $0.340 million | $0.553 million |
| Net cash used in operating activities | $(2.133) million | $(0.463) million |
*The prior period is from inception on March 11, 2022 through December 31, 2022, rather than a full fiscal year.
- Net income was $339,767, or $0.04 per basic and diluted Class A and Class B share. Income was generated by trust-account investment income, substantially offset by operating costs, franchise taxes of $137,379, and income tax expense of $528,809.
- Cash provided by investing activities was $101.011 million, primarily reflecting $100.079 million released from the trust account to redeeming shareholders and $931,751 withdrawn to pay franchise taxes.
- Cash used in financing activities was $99.079 million, including redemption payments, partly offset by proceeds from a $1.000 million convertible promissory note issued to SBC.
- At December 31, 2023, cash outside the trust account was $284,394, while marketable securities held in the trust account totaled $20.851 million.
- Current liabilities were $2.609 million, including a $1.000 million convertible promissory note, $1.001 million of excise tax payable, and $0.480 million of accrued expenses. Total liabilities were $6.634 million, including a $4.025 million deferred underwriting fee payable.
- Working capital deficit, net of income tax and franchise tax payables, was $1.129 million; accumulated deficit was $5.995 million; and stockholders’ deficit was $5.995 million.
- No operating margin is meaningful because the company had no operating revenue. The reported net margin is also not economically indicative of an operating business because net income primarily reflects trust-account investment income.
Material Changes Versus the Prior Period
- Interest and dividend income increased from $1.345 million to $2.641 million as trust-account funds generated income for a longer period.
- Operating and formation costs increased from $382,051 to $1.635 million as the company incurred public-company, due-diligence, and transaction-related expenses.
- Net income declined from $552,813 to $339,767 despite higher investment income, reflecting substantially higher operating expenses and taxes.
- Trust-account investments declined from $119.220 million to $20.851 million following the redemption of 9,577,250 Class A shares for $100.079 million in May 2023.
- The Sponsor converted 2,874,999 Class B founder shares into Class A shares on May 8, 2023.
- The proposed merger valuation was reduced from $1.2 billion to $1.0 billion in September 2023. The transaction scope was also revised to exclude certain Japanese medical corporations because of Japanese Medical Care Act restrictions on control by for-profit entities.
Guidance, Outlook, Risks, and Unusual Items
- Stockholders subsequently approved an extension of the business-combination deadline from February 9, 2024 to November 9, 2024. The filing states that failure to close a transaction by that date would require liquidation, redemption of public shares, and dissolution.
- The filing explicitly states that substantial doubt exists regarding the company’s ability to continue as a going concern because of limited cash outside the trust account, expected additional transaction costs, and the mandatory liquidation deadline.
- Management expects to need additional capital for working capital and transaction expenses. Potential working-capital loans of up to $1.5 million have been contemplated, but there is no assurance that the funds will be provided.
- The $1.000 million SBC convertible note outstanding at December 31, 2023 was amended in February 2024 to increase the principal amount to $2.700 million. The note is convertible into Class A shares at $10 per share under the stated terms.
- The merger agreement was amended several times, including to extend the outside date to March 31, 2024. A March 2024 amendment to a related non-redemption agreement contemplated closing the business combination by August 31, 2024, subject to conditions and regulatory review.
- Following a February 2024 stockholder meeting, an additional 273,334 Class A shares were redeemed, leaving approximately $17.9 million in the trust account. This occurred after the reporting date and is not reflected in the December 31, 2023 balance sheet.
- The company recorded a $1.001 million excise-tax liability associated with the May 2023 redemptions under the Inflation Reduction Act.
- Deferred underwriting commissions of $4.025 million are payable only if a business combination is completed, subject to the underwriting agreement. The underwriters agreed to waive the deferred fee if the company liquidates without completing a transaction.
- The independent auditor issued an unqualified opinion but included an explanatory going-concern paragraph. Management reported effective disclosure controls and internal control over financial reporting; no external auditor attestation was required because the company is an emerging growth company.
- The filing reports no material litigation, no off-balance-sheet arrangements, and no cybersecurity incidents since the IPO.
Most Important Facts to Verify
- Confirm that this filing belongs to Pono Capital Two, Inc., not an operating-company 10-K for SBC Medical Group Holdings Inc.
- Verify the final status, shareholder approval, regulatory clearance, financing, and closing date of the proposed SBC business combination.
- Reconcile the trust-account balance after the February 2024 redemptions with the amount available at closing and the amount available to redeeming shareholders.
- Assess whether the company can fund expenses through November 9, 2024 and whether the contemplated working-capital loans or amended SBC note are enforceable and sufficient.
- Review the final merger consideration formula, including adjustments for SBC debt, cash, net working capital, transaction expenses, escrow shares, and the reduced $1.0 billion headline valuation.
- Evaluate dilution from the 12,134,375 outstanding warrants, founder and Sponsor shares, the convertible note, potential Sponsor Shares, and any incentive shares under the non-redemption arrangements.
- Confirm treatment and payment of the $1.001 million excise-tax liability and the $4.025 million deferred underwriting fee.